{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:56:52Z","timestamp":1769511412680,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bbadis.2022.166560","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T11:24:57Z","timestamp":1664018697000},"page":"166560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A non-mitogenic FGF4 analog alleviates non-alcoholic steatohepatitis through an AMPK-dependent pathway"],"prefix":"10.1016","volume":"1868","author":[{"given":"Luyao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenliya","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuchu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianxi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongtong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengshou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongde","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lintao","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2022.166560_bb0005","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bbadis.2022.166560_bb0010","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2022.166560_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2022.166560_bb0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","article-title":"From NAFLD to NASH to cirrhosis-new insights into disease mechanisms","volume":"10","author":"Wree","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2022.166560_bb0025","first-page":"484","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus, nature reviews","volume":"17","author":"Ferguson","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbadis.2022.166560_bb0030","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.tem.2019.08.006","article-title":"Emerging molecular targets for treatment of nonalcoholic fatty liver disease","volume":"30","author":"Chen","year":"2019","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.bbadis.2022.166560_bb0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1097-2765(00)00073-3","article-title":"Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization","volume":"6","author":"Schlessinger","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbadis.2022.166560_bb0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbadis.2022.166560_bb0045","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1038\/s41467-021-27584-y","article-title":"Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects","volume":"12","author":"Ying","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2022.166560_bb0050","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/sj.onc.1207348","article-title":"HST-1\/FGF-4 plays a critical role in crypt cell survival and facilitates epithelial cell restitution and proliferation","volume":"23","author":"Sasaki","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2022.166560_bb0055","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.32404","article-title":"FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-caspase 6 signal axis","volume":"76","author":"Song","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2022.166560_bb0060","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.celrep.2017.06.063","article-title":"Uncoupling the mitogenic and metabolic functions of FGF1 by tuning FGF1-FGF receptor dimer stability","volume":"20","author":"Huang","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbadis.2022.166560_bb0065","doi-asserted-by":"crossref","first-page":"29025","DOI":"10.1073\/pnas.2010984117","article-title":"Curtailing FGF19's mitogenicity by suppressing its receptor dimerization ability","volume":"117","author":"Niu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2022.166560_bb0070","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41374-018-0074-z","article-title":"Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water","volume":"98","author":"Liu","year":"2018","journal-title":"Lab. Investig."},{"key":"10.1016\/j.bbadis.2022.166560_bb0075","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/hep.29759","article-title":"Liver-specific deficiency of unc-51 like kinase 1 and 2 protects mice from acetaminophen-induced liver injury","volume":"67","author":"Sun","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2022.166560_bb0080","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1126\/science.aay0542","article-title":"An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis","volume":"367","author":"Zhao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2022.166560_bb0085","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2014.07.018","article-title":"Cell death and cell death responses in liver disease: mechanisms and clinical relevance","volume":"147","author":"Luedde","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2022.166560_bb0090","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008656","article-title":"Caspase functions in cell death and disease","volume":"5","author":"McIlwain","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbadis.2022.166560_bb0095","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2022.166560_bb0100","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2022.166560_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","article-title":"Animal models of nonalcoholic fatty liver disease","volume":"8","author":"Hebbard","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2022.166560_bb0110","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v18.i19.2300","article-title":"Animal models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"18","author":"Takahashi","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2022.166560_bb0115","doi-asserted-by":"crossref","first-page":"21833","DOI":"10.3390\/ijms141121833","article-title":"Rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"14","author":"Imajo","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2022.166560_bb0120","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2022.166560_bb0125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature10998","article-title":"A PPAR\u03b3-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis","volume":"485","author":"Jonker","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2022.166560_bb0130","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature13540","article-title":"Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer","volume":"513","author":"Suh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2022.166560_bb0135","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1073\/pnas.1525093113","article-title":"Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease","volume":"113","author":"Liu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2022.166560_bb0140","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hep.31568","article-title":"Activating adenosine monophosphate-activated protein kinase mediates fibroblast growth factor 1 protection from nonalcoholic fatty liver disease in mice","volume":"73","author":"Lin","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2022.166560_bb0145","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10059-011-0184-6","article-title":"Time-dependent changes in lipid metabolism in mice with methionine choline deficiency-induced fatty liver disease","volume":"32","author":"Park","year":"2011","journal-title":"Mol. Cells"},{"key":"10.1016\/j.bbadis.2022.166560_bb0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrm3311","article-title":"AMPK: a nutrient and energy sensor that maintains energy homeostasis","volume":"13","author":"Hardie","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbadis.2022.166560_bb0155","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nrd1344","article-title":"AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome","volume":"3","author":"Ruderman","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbadis.2022.166560_bb0160","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cell.2018.01.007","article-title":"TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue","volume":"172","author":"Zhao","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2022.166560_bb0165","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ebiom.2018.01.008","article-title":"AMPK re-activation suppresses hepatic steatosis but its downregulation does not promote fatty liver development","volume":"28","author":"Boudaba","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbadis.2022.166560_bb0170","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.celrep.2017.03.011","article-title":"Liver-specific activation of AMPK prevents steatosis on a high-fructose diet","volume":"18","author":"Woods","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbadis.2022.166560_bb0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.celrep.2018.12.036","article-title":"Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD","volume":"26","author":"Garcia","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbadis.2022.166560_bb0180","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.cmet.2020.04.011","article-title":"Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis","volume":"31","author":"Jian","year":"2020","journal-title":"Cell Metab."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443922002319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443922002319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:15:37Z","timestamp":1760418937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443922002319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0925443922002319"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2022.166560","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A non-mitogenic FGF4 analog alleviates non-alcoholic steatohepatitis through an AMPK-dependent pathway","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2022.166560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"166560"}}